Free Trial
NASDAQ:IART

Integra LifeSciences Q3 2026 Earnings Date & Estimates

Integra LifeSciences logo
$13.85 -0.13 (-0.93%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$13.85 +0.00 (+0.01%)
As of 10/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Integra LifeSciences is estimated to report Q3 2026 earnings on Wednesday, October 21, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET

What Analysts Expect from Integra LifeSciences in Q3 2026

Integra LifeSciences is expected to post earnings of $0.5630 per share on revenue of $415.36 million. In the same quarter a year earlier Integra LifeSciences reported $0.54 per share on revenue of $402.06 million. Integra LifeSciences last reported on July 29, 2026, posting $0.56 per share and beating the $0.4805 consensus estimate. Integra LifeSciences has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.5630
Expected Revenue
$415.36 million
Prior-Year EPS
$0.54
Prior-Year Revenue
$402.06 million
Expected EPS Growth
+4.3%
Expected Revenue Growth
+3.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.56 (Beat by +$0.0795)
Last Quarter Revenue
$418.76 million
EPS Beat Rate
7 of last 8 quarters

Integra LifeSciences Q3 2026 Earnings FAQ

Integra LifeSciences (NASDAQ:IART) is estimated to report Q3 2026 earnings on Wednesday, October 21, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Integra LifeSciences' Q3 2026 earnings conference call is scheduled for Wednesday, October 21, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Integra LifeSciences to post earnings of $0.5630 per share for Q3 2026.

The consensus revenue estimate for Integra LifeSciences is $415.36 million for Q3 2026.

Integra LifeSciences Earnings Headlines

Integra LifeSciences Holdings Corporation (IART)
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel
See More Integra LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Integra LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Integra LifeSciences and other key companies, straight to your email.

About Integra LifeSciences

Integra LifeSciences (NASDAQ:IART) (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery. Integra is also known for its artificial-skin and dermal regeneration products, which are used to support the treatment of burns and other serious wounds.

Founded in 1989, Integra serves hospitals, surgical centers, and healthcare professionals in the United States and international markets. Its business is organized around technologies and products for neurosurgery and reconstructive and orthopedic surgery, with a focus on improving patient outcomes and supporting tissue repair.

View Integra LifeSciences Profile